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Telomeres are transcribed into telomeric repeat-containing RNA (TERRA), large, heterogeneous, non-
coding transcripts which form part of the telomeric heterochromatin. Despite a large number of functions
that have been ascribed to TERRA, little is known about its biogenesis. Here, we present the first
comprehensive analysis of the molecular structure of TERRA. We identify biochemically distinct TERRA
complexes, and we describe TERRA regulation during the cell cycle. Moreover, we demonstrate that
TERRA 5 ends contain 7-methylguanosine cap structures and that the poly(A) tail, present on a fraction
of TERRA transcripts, contributes to their stability. Poly(A) TERRA, but not poly(A) TERRA, is
associated with chromatin, possibly reflecting distinct biological roles of TERRA ribonucleoprotein com-
plexes. In support of this idea, poly(A) and poly(A) TERRA molecules end with distinct sequence
registers. We also determine that the bulk of 3-terminal UUAGGG repeats have an average length of 200
bases, indicating that the length heterogeneity of TERRA likely stems from its subtelomeric regions.
Finally, we find that TERRA is regulated during the cell cycle, being lowest in late S phase and peaking
in early G1. Our analyses offer the basis for investigating multiple regulatory pathways that affect TERRA
synthesis, processing, turnover, and function.
The ends of eukaryotic chromosomes, known as telomeres,
play crucial roles as guardians of genome stability and tumor
suppressors (1, 17). Human telomeres consist of tandem 5-T
TAGGG-3/5-CCCTAA-3 repeats. The guanine-rich strand
is directed in a 5-to-3 manner toward the chromosome end
and extends beyond its complement strand to form a 3 over-
hang. Telomeric DNA is associated with the six-polypeptide
shelterin complex (18), and shelterin components have been
demonstrated to protect the ends of chromosomes from being
recognized as sites of DNA damage. Human telomeres vary in
length between 5 and 15 kb, and they shorten during the course
of life, due to the so-called DNA end replication problem and
nucleolytic processing (19, 46, 47).
Telomere shortening is counteracted by telomerase, a ribo-
nucleoprotein enzyme that can extend the 3 ends of chromo-
somes. Telomerase works as a reverse transcriptase, using a
small region of its tightly associated RNA moiety as a template
for the synthesis of telomeric repeats at chromosome ends (22,
23, 29). The progressive erosion of telomeres and the activa-
tion of telomerase play key roles in chromosomal stability,
cellular immortalization, and tumor progression (7, 26). Short
telomeres elicit a DNA damage signal cascade that leads to
growth arrest and replicative senescence (16). Reactivation of
telomerase in human cancer cells allows overcoming of the
senescence barrier and is a key requisite of cancer cells to
attain unlimited proliferation potential.
Despite the fact that telomeres are heterochromatic struc-
tures, eukaryotic telomeres are transcribed into telomeric
repeat-containing RNA (TERRA) (4, 31, 40). TERRA is an
integral part of telomeric heterochromatin (4, 21, 40).
TERRA molecules are transcribed from several if not all
chromosome ends toward the telomere. They contain sub-
telomere-derived sequence and UUAGGG repeats origi-
nated from transcription of telomeric regions (4). Mamma-
lian TERRA molecules range in size from 100 bases up to at
least 9 kb and are detected exclusively in nuclear fractions.
The nuclear localization of TERRA and its enrichment at
telomeres indicate that TERRA is not translated but that it
functions as noncoding RNA (ncRNA) in telomeric and
subtelomeric heterochromatin structures. In addition, evi-
dence exists that TERRA regulates telomerase. First, in
human cells, TERRA is displaced or degraded at telomeres
by effectors of nonsense-mediated RNA decay (NMD) (4).
Among these factors, EST1A/SMG6 was identified through
its sequence similarity with the Saccharomyces cerevisiae tel-
omerase-associated protein Est1p. As yeast Est1p, human
EST1A physically interacts with telomerase (35, 37, 42).
Second, the TERRA-mimicking RNA oligonucleotides con-
taining UUAGGG repeats inhibit telomerase activity in
vitro, as determined in a telomeric repeat amplification pro-
tocol (TRAP) assay (40) as well as in direct telomerase
assays (36). TERRA oligonucleotides base pair with the
RNA template of telomerase RNA, and in addition, they are
bound by the telomerase reverse transcriptase (TERT)
polypeptide. Association of TERRA with endogenous tel-
omerase can also be detected in cellular extracts (36). It has
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been proposed that telomerase may be regulated by
TERRA in a telomere-length-dependent manner (40).
Third, genetic experiments in S. cerevisiae provide evidence
that TERRA regulates telomerase in vivo. In the rat1-1
mutant background, in which the function of the 5-3 exo-
nuclease Rat1p is reduced, TERRA is upregulated and telo-
meres are shorter than in wild-type cells due to impairment
of telomerase-mediated telomere elongation (31). Further
support for the role of TERRA in inhibiting telomerase in
vivo stems from an observation that forced telomere tran-
scription (through the use of the strong Gal promoter) leads
to telomere shortening of the transcribed telomere in cis
(39). A recent study demonstrated that, in vitro, TERRA can
form parallel G-quadruplex structures (49), but its relevance
in vivo remains unclear. TERRA was also reported to es-
tablish association of ORC complexes with shelterin pro-
teins at telomeres (21).
Despite the rather large number of functions that have been
ascribed to TERRA, little is known about its biogenesis and its
exact molecular nature. Here, we provide a detailed charac-
terization of TERRA 5 and 3 ends, determine the UUAGGG
tract length, and identify a role of the poly(A) tail in the
promotion of TERRA stability and as a marker for non-chro-
matin-associated TERRA. We also report on the cell cycle
regulation of TERRA and its low abundance in late S phase,
which we suspect is important to prevent TERRA from inter-
fering with replication of telomeric DNA. Overall, our analysis
lays the basis for further investigation of the molecular path-
ways that affect TERRA homeostasis.
MATERIALS AND METHODS
Cell cultures. The human cervical carcinoma cell line HeLa, the human pri-
mary lung fibroblast line HLF, and the human embryonic kidney cell line
HEK293 were cultured in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco) supplemented with 10% fetal calf serum (FCS) and penicillin-
streptomycin (Gibco). HeLa supertelomerase and HLF supertelomerase cell
lines were obtained from their corresponding wild-type counterparts as described
previously (15). Briefly, HeLa and HLF cell lines were first infected with pMND-
Banshee-U1-hTR, selected with G418 and then with pBabe-Hygro-hTERT, and
selected with hygromycin. After 10 to 15 days, when uninfected control cells were
dead, the selection was considered complete. Both cell lines were checked for
cooverexpression of human TERT (hTERT) and its RNA template (hTR) and
then transferred to normal medium (DMEM containing 10% FCS and penicillin-
streptomycin).
RNA preparation. Cells were trypsinized, and total RNA was prepared using
an RNeasy minikit (Qiagen) according to the manufacturer instructions.
Immunoprecipitation of TMG-capped RNAs. Immunoprecipitation (IP) of
2,2,7-trimethylguanosine (TMG)-capped RNAs was performed as described by
Chanfreau et al. (11), with some modifications. Briefly, 50 g of total RNA was
extracted from HeLa and HLF cells and incubated with 5 g of R1131 polyclonal
anti-TMG antibody (generous gift from R. Lu¨hrmann) or with 5 g of normal
rabbit IgG (sc-2027; Santa Cruz) in 300 l of IP buffer (50 mM Tris-HCl, pH 7.5,
5 mM EDTA, pH 8.0, 250 mM NaCl, 0.05% Nonidet P-40) overnight at 4°C, with
continuous rotation. The RNA-antibody complexes were coupled to 50 l of
50% slurry of protein A-Sepharose (GE Healthcare), prewashed three times with
IP buffer for 2 h at 4°C. The supernatant (SN) and precipitate (beads) were
separated by gentle centrifugation. RNAs in the supernatant were extracted
using Trizol LS (Invitrogen). The beads were washed five times with IP buffer,
and RNAs still bound to the beads were extracted with Trizol LS (Invitrogen).
RNA was transferred to positively charged nylon membranes (Hybond N; GE
Healthcare), and blots were blocked in Church buffer (0.5 M sodium phosphate
[pH 2.2], 1 mM EDTA, 7% sodium dodecyl sulfate [SDS], 1% bovine serum
albumin [BSA]) for 1 h at 50°C and then incubated with a radiolabeled telomeric
probe, obtained as described previously (4). Filters were then stripped and
reprobed for -actin and U1 snRNA.
Affinity purification of 5-capped RNAs. Affinity purification of 5-capped
RNAs was carried out as described previously (12). Briefly, purified glutathione
S-transferase (GST)–eukaryotic translation initiation factor 4E (eIF4E) (1 mg)
was nutated with glutathione agarose beads in 1 phosphate-buffered saline
(PBS) for 1 h at 4°C. The beads were washed four times with 1 PBS. A portion
(200 g) of the immobilized GST-eIF4E fusion protein was washed three times
with buffer A (10 mM KHPO4, pH 8, 100 mM KCl, 2 mM EDTA, 5% glycerol,
100 g/ml yeast tRNA, 6 mM dithiothreitol [DTT], 1.3% polyvinyl alcohol,
Triton X-100, 1 U/l SuperaseIN [Ambion]) and then incubated with 50 g of
HeLa and HLF total RNA, preheated to 75°C for 5 min at room temperature.
After 1 h, the supernatant was collected and the beads were washed five times
with 1 ml of buffer B (same as buffer A but lacking yeast tRNA). RNA retained
on the beads, as well as RNA present in the supernatant fraction, was extracted
using an RNeasy minikit (Qiagen) according to the manufacturer instructions.
As a control, the same amount of GST protein alone was used. RNA was then
loaded onto 1.2% formaldehyde agarose gels and separated by electrophoresis.
RNA was transferred to positively charged nylon membranes (Hybond N; GE
Healthcare), and blots were treated as described above. Filters were then
stripped and reprobed for -actin and 5.8S rRNA.
Isolation of poly(A) and poly(A) RNA fractions. Total RNA from HeLa
cells was prepared, and poly(A) and poly(A) fractions were separated using
an oligo(dT) resin (Oligotex; Qiagen) according to the manufacturer instruc-
tions.
Subcellular fractionation. HEK293 cells (107) were resuspended in 100 l
cytosolic extraction buffer (CEB) (10 mM HEPES-KOH, pH 7.9, 10 mM KCl,
0.34 M sucrose, 1.5 mM MgCl2, 1 Complete protease inhibitor cocktail
[Roche], 0.5 mM DTT, 0.1 U/l SuperaseIN [Ambion]). Next, 100 l CEB
containing in addition 0.2% Nonidet P-40 (AppliChem) was added, and the
mixture was incubated for 5 min at 4°C on a rotating wheel. After centrifu-
gation for 5 min at 1,290  g, the supernatant (SN) was saved as cytosolic
extract (cy). The pellet was washed once with 100 l CEB. Nucleoplasmic
extract was prepared by resuspending the 107-cell-equivalent pellet in 100 l
nucleoplasmic extract buffer (NPEB) (140 mM NaCl, 50 mM Tris-HCl, pH
7.5, 1.5 mM MgCl2, 0.5% Nonidet P-40, 1 Complete protease inhibitor
cocktail, 0.5 mM DTT, 0.1 U/l SuperaseIN), and nuclear membranes were
disrupted by 20 strokes with a tight-fitting type B pestle using a Dounce
homogenizer, followed by rotation for 20 min at 4°C. After centrifugation at
10,000  g, the SN was saved as nuclear extract (nucl). The pellet was treated
with 50 l DNase digestion mix (74 kU/ml DNase I in 1 RDD buffer
[Qiagen]) for 1 h at 37°C. After centrifugation at 10,000  g and 4°C for 5
min, the chromatin was extracted with 50 l chromatin extraction buffer (500
mM NaCl, 50 mM Tris-HCl, pH 7.5, 1.5 mM MgCl2, 0.5% Nonidet P-40, 1
Complete protease inhibitor cocktail, 0.5 mM DTT, 0.1 U/l SuperaseIN) for
20 min at 4°C. Following centrifugation for 5 min at 10,000  g and 4°C, the
SN was kept as chromatin extract (chrom). Subcellular fractionation was
evaluated by Western blot analysis. An equivalent of 5  105 cells was mixed
with Laemmli SDS loading buffer (1.5% SDS, 62.5 mM Tris-HCl, pH 6.8,
10% sucrose, 0.04% bromophenol blue, 5% beta-mercaptoethanol), sepa-
rated on a 4 to 20% gradient gel (Lonza), and transferred to a nitrocellulose
membrane (GE Healthcare). After the mixture was blocked in blocking
solution (5% milk, 0.2% Tween 20, 1 PBS) for 30 min at room temperature,
the membrane was incubated with the corresponding primary antibodies in
blocking solution overnight at 4°C. The following antibodies were used:
anti-hnRNP A1, clone 4B10 (1:2,000; Santa Cruz Biotechnologies); anti-
H3Ac, 06-599 (1:1,000; Upstate); anti--tubulin, clone B-5-1-2 (1:2,000;
Sigma); anti-Dis3, clone T-20 (1:2,000; Santa Cruz Biotechnologies); and
anticoilin, ab11822 (1:1,000; Abcam). After the mixture was washed three
times for 5 min each in PBS-T (0.2% Tween 20, 1 PBS), the membrane was
incubated with the corresponding anti-mouse horseradish peroxidase (HRP)-
conjugated or anti-rabbit HRP-conjugated IgG in blocking solution for 1 h at
room temperature (both 1:2,000; Promega). After three 5-min washes in
PBS-T (0.2% Tween 20, 1 PBS), the signal was revealed using ChemiGlow
ECL substrate (Alpha Innotech) and a FluorChem 8900 apparatus (Alpha
Innotech).
Real-time reverse transcription-PCR (RT-PCR) analysis. Total RNA was
reverse transcribed with -actin- and telomere-specific primers [(CCCTAA)5]
(listed in Table S1 in the supplemental material) at 55°C using SuperScript III
reverse transcriptase (Invitrogen). For SYBR green reactions, four different
TERRA transcripts, generated from four distinct chromosome ends (10q, 15q,
XpYp, and XqYq), were analyzed using specific oligonucleotides listed in Table
S1. TERRA levels were normalized against -actin signals (primers listed in
Table S2 in the supplemental material). Real-time PCR analysis was performed
using Power SYBR green PCR master mix (Applied Biosystems). Relative quan-
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tification of TERRA and gene transcripts was performed using the comparative
threshold cycle method.
In vitro RNA polyadenylation. Total RNA (5 g) was heated to 70°C for 5 min
and then incubated with 360 U of yeast poly(A) polymerase (Pap1) for 10 min at
37°C (30).
Telomeric UUAGGG reverse transcription. When indicated, 5 g of total
RNA was treated with yeast poly(A) polymerase (Pap1) as described above.
Total or poly(A) RNA from different cell lines was reverse transcribed with
SuperScript III (Invitrogen) in the presence of 5 l of [-32P]dCTP (3,000
Ci/mmol, 10 Ci/l), 5 M unlabeled dCTP, 500 M dTTP, and 500 M dATP.
After 1 h, the reaction was chased with 500 M unlabeled dCTP and 500 M
dGTP, and another 1 l of SuperScript III (200 U/l) was added. For the
dGTP reaction, only 500 M unlabeled dCTP and 1 l of SuperScript III were
added during the chase. The reaction was carried out at 50°C using six different
TERRA-specific RT primers (see Table S3 in the supplemental material), which
contained oligo(dT)21 at their 5 ends and which ended in -CCC-3, -CCT-3,
-CTA-3, -TAA-3, -TTC-3, or -TCC-3. The length of the derived cDNA was
measured on a 1% denaturing alkaline agarose gel.
In vitro transcription of UUAGGG repeat-containing RNAs with T7 RNA
polymerase. A DNA fragment containing 348 bp of pure telomeric TTAGGG
repeats was cloned into HindIII/BamHI-cut pLitmus 28i (New England Biolabs),
resulting in telo-350 pLitmus 28i. telo-350 pLitmus 28i was cleaved, and another
DNA fragment, containing the chromosomal XpYp (Chr XpYp) subtelomere-
derived sequence (100 bases) followed by a block of polymorphic TTAGGG-like
repeats (250 bases), was inserted upstream of the TTAGGG repeats. The re-
sulting plasmid (XpYp telo-350 pLitmus 28i) was digested with PvuII and
BsmBI, gel purified, and used as a template (100 ng) for in vitro runoff tran-
scription using T7 RNA polymerase (MEGAscript; Ambion) according to the
manufacturer’s instructions.
In order to generate a template for the transcription of an RNA containing 696
bases of pure UUAGGG repeats, telo-350 pLitmus 28i was cut with PvuII and
BsmBI. The resulting fragment was gel purified and ligated in vitro with the pure
telomeric DNA fragment obtained from the digestion of the telo-350 pLitmus 28i
plasmid with BbsI and BamHI. The ligation was performed with T4 DNA ligase
(New England Biolabs) for 5 min at 16°C. The ligation product was purified from
the gel, digested with BsmBI, and then used as a template (100 ng) for T7-
mediated in vitro transcription (MEGAscript; Ambion). Thus, a DNA template
that ends with a TTAGGG repeat was generated. In vitro transcripts were
purified on 4% polyacrylamide gels and used as substrates for polyadenylation
reactions.
Terminal restriction fragment (TRF) analysis. Genomic DNA was prepared
using a Wizard genomic DNA kit (Promega). RsaI- and HinfI-digested DNA was
fractionated on a 0.8% agarose 0.5 Tris-borate-EDTA (TBE) gel by using a
pulsed-field gel electrophoresis (PFGE) apparatus (Rotaphor; Biometra) at 4.3
V/cm for 18 h at 10°C, followed by ethidium bromide staining. The gel was dried,
denatured, and hybridized for 16 h at 50°C with a randomly labeled telomeric
probe.
Cell cycle analysis. HeLa cells were synchronized using a double thymidine
block (early-S-phase block). Briefly, HeLa cells were seeded at 10% of conflu-
ence. After 24 h, they were incubated with 2 mM thymidine for 18 h. After the
first thymidine block, the cells were released for 9 h by three washes in 1 PBS
and by addition of fresh DMEM. Following the release, the cells were incubated
again with 2 mM thymidine, for 17 h. After this second block, the thymidine was
removed and cells were released as after the first block. Total RNA was extracted
at the times indicated in Fig. 6 and analyzed by quantitative RT-PCR (qRT-
PCR). Cell cycle synchronization was evaluated with propidium iodide (PI)
staining and fluorescence-activated cell sorter (FACS) analysis. For PI staining,
5  105 cells were washed in 1 PBS and fixed in 1 ml of cold 70% ethanol. Cell
pellets were resuspended in 0.5 ml of 1 PBS containing 0.2 g/ml RNase A,
incubated at 37°C for 15 min, and stained with 80 g/ml PI (Sigma) for 15 to 20
min at 4°C. Cells were analyzed using a CyAn ADP analyzer.
RESULTS
7-Methylguanosine cap structure at TERRA 5 ends.
TERRA is transcribed from several telomeres by RNA poly-
merase II (Pol II) (4, 31, 40). mRNAs generated by Pol II
have a 7-methylguanosine (m7G) cap structure (41), but
snRNAs contain a peculiar 5-end cap structure character-
ized by a double methylation of the nitrogen atom at posi-
tion 2 of the m7G to form the 2,2,7-trimethylguanosine
(TMG) cap (14). The presence of a TMG cap on snRNAs is
believed to prevent leaking transport to the cytoplasm (14).
Since TERRA is found exclusively in the nucleus, we first
evaluated the presence of TMG cap structures on its 5 end.
Cap-containing RNAs were immunoprecipitated from HeLa
and HLF total RNAs with the R1131 polyclonal antibody,
which shows high specificity for the TMG cap structure (25).
The TMG cap-containing U1 snRNA served as a positive
control and -actin mRNA as a negative control. Following
selective immunoprecipitation, RNA was extracted and an-
alyzed by Northern blotting using a strand-specific TERRA
probe (4). This revealed that TERRA molecules do not
contain a TMG cap structure (Fig. 1A).
To determine whether TERRA contains a canonical m7G
cap, we isolated total RNA from HeLa and HLF cells and
selected m7G cap-containing RNAs by using the high-affinity
m7G cap-binding protein eIF4E fused to glutathione S-trans-
ferase (GST) that had been immobilized on a glutathione
column. As a control, total RNA was incubated with GST
protein alone. Northern blot analysis was carried out using a
strand-specific TERRA probe. -Actin and 5.8S rRNA were
included as positive and negative controls, respectively. The
analysis revealed that TERRA bound to the GST-eIF4E pro-
tein, indicating that the large majority of TERRA contains the
m7G cap (Fig. 1B).
Poly(A) tail stabilizes TERRA transcripts. Around 7% of
human TERRA is polyadenylated (2). The mechanism of
TERRA polyadenylation remains unclear, as a canonical
5-AAUAAA-3 poly(A) signal is predicted to be missing in
primary TERRA transcripts. Canonical polyadenylation in-
creases the transcript stability, whereas noncanonical
poly(A) polymerases, which add short poly(A) tails to their
substrate RNAs, usually trigger efficient decay of the RNAs
by the recruitment of the nuclear exosome complex (28, 43,
44, 48). We blocked transcription in HeLa cells with 5 g/ml
actinomycin D and measured TERRA levels in poly(A)
and poly(A) RNA fractions in time course experiments by
Northern blotting (Fig. 2). -Actin, c-Myc, and U1 snRNA
were included in the analysis for normalization (U1 snRNA
and -actin) and fractionation and to control for successful
inhibition of Pol II (c-Myc) (half-life [t1/2] of 20 min [24, 27,
45]) (Fig. 2). Quantification of the hybridization signals on
a PhosphorImager revealed that poly(A) TERRA has a
half-life of about 3 h and poly(A) TERRA has a very long
half-life of more than 8 h (Fig. 2). Therefore, the poly(A)
tail increases TERRA stability, suggesting that the canoni-
cal poly(A) polymerase is responsible for the polyadenyla-
tion of this TERRA population.
Poly(A) and poly(A) TERRA fractions have different sub-
nuclear distributions. TERRA is nearly exclusively nuclear
and partially colocalizes with telomeres, where it may elicit
some of its biological functions. In order to further character-
ize poly(A) and poly(A) TERRA, we developed a fraction-
ating protocol to distinguish chromatin-associated, nucleoplas-
mic, and cytoplasmic TERRA populations (Fig. 3) (also see
Materials and Methods). The protocol was applied to HEK293
cells, and the identity of subcellular fractions was confirmed by
Western blot analysis with antibodies specific for -tubulin
(cytoplasm [cy]), Dis3 (cy and nucleoplasm [nucl]), coilin (nucl
and chromatin associated [chrom]), hnRNP A1 (nucl and
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chrom), and H3Ac (chrom) (Fig. 3A). Poly(A) and poly(A)
RNA was isolated from each subcellular fraction, and TERRA
levels were measured by Northern blotting and qRT-PCR (Fig.
3A and B). U1 snRNA, -actin, NEAT1, and XIST were
included in these analyses as RNA controls of the subcellular
and poly(A) and poly(A) fractionation. NEAT1 is a 4-kb
polyadenylated ncRNA that is an integral component of nu-
clear paraspeckles (13). XIST ncRNA associates with and si-
lences the inactive X chromosome (8, 9). As shown in Fig. 3B
and C, 60% of poly(A) TERRA was found in the nucleo-
plasmic extracts, and the remaining 40% was found associ-
ated with chromatin. On the contrary, the vast majority (80%)
of poly(A) TERRA was present in the nucleoplasmic frac-
tion, while it was barely detectable on chromatin (Fig. 3B and
C). As expected, both TERRA populations were almost not
present in the cytoplasmic extracts. The faint signals detected
in this fraction (	10%) may be due to leakage out of the
nucleus during cell fractionation (Fig. 3B and C). Overall,
these findings indicated that chromatin-associated TERRA is
not polyadenylated, whereas poly(A) TERRA accumulates in
the nucleus, binding only weakly and/or transiently to telo-
meric or other chromatin.
The majority of TERRA UUAGGG tracts are shorter than
400 bases. The length heterogeneity of TERRA may be due
to heterogeneity of TERRA 5 ends, variation of UUAGGG
tract length at TERRA 3 ends, or both. To address this
issue, we developed an RT protocol to measure the UU
AGGG tract length. Isolated RNA was reverse transcribed
with a mixture of six oligonucleotides that were predicted to
hybridize to the junction between the UUAGGG sequence
in all six permutated registers and the poly(A) tail of
poly(A) TERRA (Fig. 4A). In order to also analyze the
UUAGGG tract length in the poly(A) TERRA population
with the same RT primers, we polyadenylated TERRA in
vitro with recombinant yeast Pap1 prior to the analysis (Fig.
4A). RT was first carried out in the presence of only three
nucleotides ([32P]dCTP, dTTP, and dATP) in order to re-
strict reverse transcription to the pure UUAGGG tract. The
length of the derived cDNA was measured on a 1% dena-
turing alkaline agarose gel (Fig. 4B). The 1-h pulse was
followed by a chase reaction in which an excess of unlabeled
dCTP and, for the dGTP reaction, dGTP was added in
order to allow RT beyond the cytosine-containing subtelo-
meric TERRA sequence. With dGTP, the majority of the
shorter products were chased into longer cDNAs, indicating
that the lack of dGTP, which is required to reverse tran-
scribe beyond cytosine bases, was the major cause of the
length restriction during the pulse.
In control experiments, we tested the efficiency of the RT
on two different synthetic UUAGGG repeat-containing
transcripts. The first transcript, referred to as XpYp telo-
350, contains a subtelomere-derived sequence (100 bases,
cloned from the terminal part of Chr XpYp) and a block of
polymorphic UUAGGG-like repeats (250 bases) followed
by pure telomeric UUAGGG repeats (348 bases). The sec-
ond transcript, referred to as telo-700, contains only pure
telomeric UUAGGG repeats, with a length of 696 bases.
Under the employed experimental conditions, the reverse
transcriptase efficiently reverse transcribed both UUAGGG
repeat-containing transcripts (see Fig. S1A in the supple-
mental material). Also, as expected, the XpYp telo-350 RT
product was efficiently chased into a longer RT product
upon addition of dGTP. However, it is worth noting that the
RT product from the telo-700 transcript was somewhat
FIG. 1. TERRA molecules contain an m7G cap structure but not a TMG cap structure at their 5 ends. (A) Immunoprecipitation of total RNA
from HeLa and HLF cells with R1131 anti-TMG antibody. Input and supernatant (SN) material were loaded at 25%. (B) Affinity purification of
m7G cap-containing RNAs, followed by Northern blot analysis. Total RNA from HeLa and HLF cells was selectively enriched for RNAs containing
the m7G cap by affinity purification using eIF4E (the high-affinity cap binding protein) fused to glutathione S-transferase (GST). Input and SN
material were loaded at 100%.
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weaker and more smeary than the RT product of XpYp
telo-350, indicating that an increased number of truncated
cDNAs are produced when long UUAGGG repeats are
reverse transcribed (see Fig. S1A). However, when we re-
verse transcribed the two in vitro transcripts together or in
combination with total RNA from HeLa cells, we did ob-
serve the expected bands corresponding to XpYp telo-350
and telo-700, and no preferential RT of short-UUAGGG-
tract-containing RNA was observed (see Fig. S1B).
In another control experiment, cDNAs derived from -ac-
tin and GUSB mRNAs were undetectable when the RT was
carried out in the absence of dGTP (see Fig. S2 in the
supplemental material). On the contrary, after the chase,
both of these mRNAs were reverse transcribed, as they
could be detected by RT-PCR. The same was true for
TERRA molecules derived from chromosome end XpYp, in
which subtelomeric cDNA could be detected by PCR only
after the chase (see Fig. S2).
The same protocol was applied to RNA from HeLa and
HLF cells. As shown in Fig. 4B, this experiment suggests
that the majority of both the total TERRA [93% of which is
comprised of poly(A) TERRA] and the poly(A) TERRA
fraction has a pure UUAGGG tract length ranging from 100
bases to 400 bases, with a median length of 200 bases in both
cell lines. Furthermore, to test whether changes in telomeric
length may affect the size of the UUAGGG tract, we per-
formed the same analysis in supertelomerase HeLa and
HLF cells, which have overelongated telomeres (see Fig. S3
in the supplemental material) due to the cooverexpression
of hTR and hTERT (15). However, even in the presence of
overelongated telomeres, no significant change in the length
of UUAGGG repeats was detected (Fig. 4B). This suggests
that TERRA transcription does not proceed far into the
telomeric tract, although posttranscriptional trimming can-
not be excluded. Nonetheless, the results indicate that
TERRA length heterogeneity is mainly due to size variabil-
ity of its subtelomeric tract.
Poly(A) and poly(A) TERRA differ in their termination
sites. TERRA 3 ends can potentially terminate at six different
positions within the UUAGGG repeat sequence. To deter-
mine TERRA 3-end sequences, we performed UUAGGG-
specific reverse transcription reactions as described above but
using in separate reactions the six different TERRA-specific
primers that contained oligo(dT) at their 5 ends and that
annealed with their three most-3-terminal bases to the
TERRA 3 end, in case of base complementarity. Therefore,
these primers ended in -CCC-3, -CCT-3, -CTA-3, -TAA-3,
-TTC-3, or -TCC-3. As described above, in order to also
characterize termination sites in the poly(A) TERRA pop-
ulation, we polyadenylated total RNA with recombinant
yeast Pap1 prior to reverse transcription. In a control ex-
periment with synthetic RNA oligonucleotides that ended in
all possible telomeric registers, we found that Pap1 elon-
gates all 3 ends with similar efficiencies (see Fig. S4 in the
supplemental material). As seen with total RNA extracted
from HeLa and HLF cells (Fig. 5A), we obtained the
most efficient TERRA reverse transcription with the 5-(dT)21CCT-
3 primer, indicating that poly(A) TERRA preferentially ter-
minates with UUAGG-3.
With the poly(A) TERRA fraction, however, we found
that two different primers, 5-(dT)21-TAA-3 and 5-(dT)21-
AAC-3, produced the strongest signals. Both of these primers
hybridize to and recognize the same frame, indicating that
poly(A) addition occurs most frequently after the second uracil
or the adenosine within the UUAGGG repeats (Fig. 5B). The
different termination sites of poly(A) and poly(A) TERRA
transcripts support the idea of unrelated 3 processing events
for these distinct RNA populations.
TERRA is regulated in a cell cycle-dependent manner. To
assess whether TERRA is regulated during the cell cycle, we
synchronized HeLa cells near the G1/S boundary by using a
double thymidine block. In order to exclude possible effects
of the cell cycle arrest and checkpoint activation on TERRA
abundance, we analyzed TERRA levels only after the sec-
ond G1 phase from the release in a time course experiment.
Total RNA from HeLa cells was extracted from 12 h (sec-
FIG. 2. Poly(A) TERRA has a longer half-life than poly(A)
TERRA. HeLa cells were treated with 5 g/ml actinomycin D for
the indicated times. Total RNA was prepared from HeLa cells, and
poly(A) RNA was separated from poly(A) RNA by using an
oligo(dT) resin. Both RNA fractions were subjected to Northern
blot analysis using a telomeric DNA probe detecting UUAGGG
repeats. Filters were then stripped and reprobed successively for
c-Myc RNA and -actin and U1 snRNA. The TERRA half-life in
poly(A) and poly(A) fractions was calculated using a scatter plot
analysis after the TERRA signal was normalized to the U1 and
-actin signals, respectively. The best-fit exponential regression
curve of the data points was determined for both fractions. R2
values are indicated.
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ond G1 phase) to 26 h (third G1 phase) after the release
from the block, at intervals of 2 h. Cell cycle progression was
monitored by FACS analysis (Fig. 6A). TERRA molecules
derived from four different chromosome ends (10q, 15q,
XpYp, and XqYq) were assessed by qRT-PCR and normal-
ized to -actin mRNA. For all TERRA molecules, we ob-
served the highest levels in early G1. TERRA levels de-
creased slightly in late G1 and plunged in S phase, reaching
the lowest expression levels as cells progressed from late S
to G2 phase. After cells had passed through G2 and M
phases and reentered the next G1 phase, TERRA expression
increased, again reaching the initial expression values (Fig.
6B). Notably, TERRA levels in G1 were 3 to 10 times higher
than in late S/G2. Low levels of TERRA in late S phase may
FIG. 3. Subcellular localization of poly(A) and poly(A) TERRA fractions. (A) HEK293 cell cytoplasmic (cy), nucleoplasmic (nucl),
and chromatin (chrom) soluble fractions were prepared and analyzed by Western blotting. Detection of -tubulin (cy), Dis3 (cy and nucl),
coilin (nucl and chrom), hnRNP A1 (nucl and chrom), and H3Ac (chrom) was used to confirm HEK293 cell fractionation. (B) Total,
poly(A), and poly(A) RNA was prepared from each HEK293 subcellular fraction and monitored for TERRA transcriptional levels by
Northern blot analysis. (C) TERRA fractionation was also evaluated by qRT-PCR after the TERRA signals were normalized to the
enhanced green fluorescent protein (eGFP) signal. eGFP RNA was produced in a T7 in vitro reaction and added to each subcellular fraction
before RNA extraction proceeded. -Actin [poly(A)] (cy), U1 snRNA [poly(A)] (nucl and chrom), NEAT1 [poly(A)] (nucl), and XIST
[poly(A)] (chrom) were used as controls for HEK293 cell fractionation. Error bars indicate standard deviations (SD).
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prevent deleterious interference with DNA replication of
telomeric tracts, which is seen under circumstances in which
TERRA is upregulated at telomeres (4, 50).
DISCUSSION
The notion that the ends of eukaryotic chromosomes are tran-
scribed into RNA and that telomeric chromatin contains RNA
molecules adds a new fascinating level of complexity to telomere
metabolism and provides another example of a structural RNA
molecule that may prove to be of relevance. A detailed under-
standing of TERRA structure and biogenesis is of fundamental
importance in order to elucidate its enigmatic functions. Here we
provide a first in-depth analysis of the primary structures of
TERRA molecules.
Since TERRA is very heterogeneous in length, it seemed con-
ceivable that TERRA 5 ends are trimmed posttranscriptionally
and therefore are uncapped. However, our data demonstrate that
the vast majority of TERRA 5 ends harbor a canonical m7G cap
structure. This therefore indicates that TERRA 5 ends are gen-
erated cotranscriptionally and are not due to posttranscriptional
FIG. 4. The UUAGGG tract of TERRA molecules is not longer than 400 bases. (A) Schematic representation of UUAGGG tract-specific
reverse transcription. (B) Total RNA from HeLa and HLF (wild type and supertelomerase [supertelo] [hTERT and hTR overexpressed])
cells was treated or not treated with yeast Pap1. A radioactive reverse transcription was performed with an oligo(dT)21NNN, where NNN
corresponds to a sequence able to guide the annealing of the oligo(dT) itself at the junction between the poly(A) tail and the UUAGGG
repeats. When the reaction is carried out in the absence of dGTP, only the UUAGGG portion of TERRA can be reverse transcribed.
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processing. The 5-end cap modification should protect TERRA
from the action of 5-to-3 exonucleases, in analogy to other
capped RNAs (33). Although transcribed by Pol II, the majority
(90%) of TERRA molecules are not polyadenylated, resem-
bling in terms of 5- and 3-end structures some other Pol II
transcripts (histone mRNAs) that contain a 5 cap but not a
poly(A) tail (34).
We identify remarkable differences in biochemical behavior
between the poly(A) and poly(A) TERRA fractions.
Poly(A) TERRA is more stable, making it unlikely that a
noncanonical polyadenylation pathway, which channels RNAs
toward exosome-mediated RNA degradation, is responsible
for polyadenylation (43). How the canonical poly(A) polymer-
ase may polyadenylate TERRA remains to be explored, as the
classical cleavage and polyadenylation signals appear to be
missing in the TERRA sequence. Moreover, poly(A) and
poly(A) TERRA fractions differ in termination sequence.
Finally, poly(A) TERRA behaves differently during nuclear
fractionation, being mostly in a non-chromatin-associated pool
whereas a considerable fraction of poly(A) TERRA is chro-
matin associated. Together, these findings suggest distinct pro-
cessing pathways and biological functions for poly(A) and
poly(A) TERRA populations. Why poly(A) but not
poly(A) TERRA is released from the chromatin remains
unclear. It will also be interesting to determine whether or not
telomerase associates specifically with the nucleoplasmic or
chromatin-associated TERRA pool. If TERRA regulates telo-
merase in a telomere-specific manner, one would expect spe-
cific association of telomerase with chromatin-associated
poly(A) TERRA molecules. The nucleoplasmic TERRA
pool might, on the other hand, have effects on overall telomere
length and/or might be involved in biological functions not yet
revealed.
Another fundamental question concerning the biology
and the homeostasis of TERRA regards its length hetero-
geneity. Human TERRA ranges from 100 bases up to
more than 9 kb (4). Here, we develop a new reverse
transcription strategy to measure the pure telomeric UU
FIG. 5. Poly(A) and poly(A) TERRA fractions have different termination sequences. (A) UUAGGG tract reverse transcription was
performed on total RNA from HeLa and HLF cells treated with yeast Pap1. Six different primers were used in six different reactions. Each primer
consists of an oligo(dT)21NNN, where the last three positions are a single combination of dCTP, dTTP, and dATP. The use of six different
oligonucleotides allows discrimination between all of the possible termination sites. (B) The same approach was used to identify a preferential
register between the UUAGGG repeats and the poly(A) tail in the TERRA poly(A) fraction. Numbers at the bottom of each panel indicate the
percentage of TERRA cDNA produced by each specific primer. The total TERRA cDNA value was calculated as the sum of the single signals.
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AGGG tract length. Recently, it has been shown that
TERRA transcription start sites at 19 different chromosome
ends contain CpG islands, which, according to database
entries, are located not more than 1 kb upstream of the
predicted telomeric regions (32). This finding led us to con-
sider that the heterogeneity of TERRA might stem from its
telomeric region. However, the reference sequences from
the NCBI database do not take into account the blocks of
polymorphic (TTAGGG)n-like repeats (38), which are in-
terspersed with canonical (TTAGGG)n repeats and extend
for at least 1 kb (5). Our results now suggest that the ma-
jority of both poly(A) and poly(A) fractions have UU
AGGG tract sizes of approximately 200 bases, with little
length heterogeneity. Although we cannot rule out the ex-
istence of a subset of TERRA molecules with long UU
AGGG repeats, our data suggest that, mostly, TERRA tran-
scription does not proceed far into the telomeric tract. In
support of this conclusion, a recent study demonstrates par-
tial transcriptional blockage occurring during transcription
of guanine-rich DNA in vitro (6). In summary, we conclude
that TERRA length heterogeneity is mostly due to length
differences of the sequences that are derived from polymor-
phic (TTAGGG)n-like repeats and other sequences of the
subtelomeric region.
Finally, we also identify that TERRA levels change in a
cell cycle-dependent manner. TERRA accumulates in early
G1, continuously decreases in S phase, and reaches the low-
est expression levels at the transition between late S and G2.
TERRA inhibits telomerase both in vitro (36, 40) and in vivo
(31, 36). Therefore, downregulation of TERRA in S phase
might unleash telomerase, allowing the extension of the
telomeric G-rich strand in a cell cycle-dependent manner.
Downregulation of TERRA in S phase may also be critical
to allow efficient replication of chromosome ends by the
canonical DNA replication machinery. Indeed, depletion of
RNA surveillance factors, which were shown to interact with
the replication machinery (3, 10), leads to accumulation of
TERRA at chromosome ends and coincides with stochastic
loss of entire telomere tracts (4). A similar phenotype is
seen in cells derived from patients suffering from ICF (im-
munodeficiency, centromere instability, facial anomalies)
syndrome, which contain defective DNA methyltransferase
DNMT3b. Cell lines derived from ICF patients show high
TERRA levels, and they suffer from frequent telomere loss
(20, 32, 50).
In conclusion, our study investigates fundamental aspects
of TERRA homeostasis, providing evidence for the exis-
tence of multiple regulatory pathways for TERRA biogen-
esis, turnover, and subnuclear localization. This lays the
basis for further investigations on TERRA regulatory path-
ways, which promise to provide insight into the functions of
this fascinating RNA.
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